A. d’Arminio Monforte

发表

Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study

A. Mocroft, R. Brettle, O. Kirk, 2002, AIDS.

Anxiety and depression symptoms after virological clearance of COVID‐19: A cross‐sectional study in Milan, Italy

A. d’Arminio Monforte, F. Bai, D. Tomasoni, 2020, Journal of medical virology.

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Erwan L'Her, Alexander Zoufaly, Marco Massari, 2020, The New England journal of medicine.

The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection.

A. d’Arminio Monforte, G. Ippolito, A. Lazzarin, 2012, The new microbiologica.

Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy

A. d’Arminio Monforte, S. Romagnoli, C. Tincati, 2016, AIDS.

Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.

A. d’Arminio Monforte, F. Baldanti, F. Ceccherini‐Silberstein, 2012, The new microbiologica.

Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

A. d’Arminio Monforte, P. Reiss, A. Pharris, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Late presentation of HIV infection: a consensus definition

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2011, HIV medicine.

Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

A. Mocroft, A. d’Arminio Monforte, C. Sabin, 2018, Journal of the International AIDS Society.

Abacavir use and risk of recurrent myocardial infarction

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2018, AIDS.

Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration

A. Mocroft, A. d’Arminio Monforte, R. Weber, 2016, BMC Medicine.

Associations between immune depression and cardiovascular events in HIV infection

A. Mocroft, A. d’Arminio Monforte, R. Weber, 2013, AIDS.

Combination antiretroviral therapy and the risk of myocardial infarction

Rodolphe Thiébaut, Peter Reiss, Nina Friis-Møller, 2003 .

Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.

J. Sterne, O. Kirk, A. d’Arminio Monforte, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV

A. d’Arminio Monforte, A. Antinori, G. Marchetti, 2021, BMC Infectious Diseases.

Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients

J. Sterne, A. Mocroft, A. d’Arminio Monforte, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011.

M. Moroni, A. d’Arminio Monforte, A. Lazzarin, 2011, The new microbiologica.

Cause‐specific mortality after diagnosis of cancer among HIV‐positive patients: A collaborative analysis of cohort studies

J. Sterne, A. d’Arminio Monforte, P. Reiss, 2020, International journal of cancer.

Impact of daily versus weekly service of infectious diseases consultation on hospital antimicrobial consumption: a retrospective study

A. d’Arminio Monforte, Andrea Cona, Ottavia Viganò, 2020, BMC Infectious Diseases.

Risk of tuberculosis following HIV seroconversion in high-income countries

C. Morrison, A. d’Arminio Monforte, C. Sabin, 2012, Thorax.

Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study

A. d’Arminio Monforte, G. Ippolito, A. Antinori, 2001, Journal of NeuroVirology.

The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges

A. d’Arminio Monforte, C. Sabin, P. Reiss, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Better mind the gap: addressing the shortage of HIV-positive women in clinical trials

A. d’Arminio Monforte, S. Walmsley, L. Sherr, 2010, AIDS.

Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers

A. Mocroft, A. d’Arminio Monforte, C. Sabin, 2017, PloS one.

Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART

A. d’Arminio Monforte, M. Clerici, F. Bai, 2010, AIDS.

Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy.

Richard D Moore, J. Robins, M. Hernán, 2016, International journal of epidemiology.

Elevated triglycerides and risk of myocardial infarction in HIV-positive persons

O. Kirk, A. d’Arminio Monforte, C. Sabin, 2011, AIDS.

Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis

A. d’Arminio Monforte, G. Ippolito, A. Antinori, 2012, BMC Health Services Research.

The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case–control study

A. d’Arminio Monforte, M. Capobianchi, L. Iacoviello, 2013, BMC Infectious Diseases.

Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2014, The Journal of antimicrobial chemotherapy.

Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting

A. Mocroft, A. d’Arminio Monforte, H. Günthard, 2022, Open forum infectious diseases.

HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review

A. d’Arminio Monforte, J. V. van Wyk, S. Di Giambenedetto, 2021, Infectious Diseases and Therapy.

Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors

A. d’Arminio Monforte, M. Augello, G. Marchetti, 2022, Frontiers in Immunology.

Presence of the Metabolic Syndrome Is Not a Better Predictor of Cardiovascular Disease Than the Sum of Its Components in HIV-Infected Individuals

A. d’Arminio Monforte, C. Sabin, P. Reiss, 2009, Diabetes Care.

Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study

A. d’Arminio Monforte, P. Lorenzini, G. Guaraldi, 2019, European Journal of Clinical Microbiology & Infectious Diseases.

European AIDS Clinical Society Standard of Care meeting on HIV and related coinfections: The Rome Statements

A. Mocroft, A. d’Arminio Monforte, J. Lundgren, 2016, HIV medicine.

Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus

A. d’Arminio Monforte, A. Antinori, P. Lorenzini, 2015, PloS one.

Partnership of HIV-infected women and health status.

A. d’Arminio Monforte, G. Ippolito, E. Girardi, 2005, Journal of acquired immune deficiency syndromes.

Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study *

O. Kirk, A. d’Arminio Monforte, R. Weber, 2011, HIV medicine.

Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, The Journal of antimicrobial chemotherapy.

Out of focus: tailoring the cascade of care to the needs of women living with HIV

A. d’Arminio Monforte, M. Loutfy, M. Boffito, 2017, HIV medicine.

Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia

A. d’Arminio Monforte, M. Massari, M. Pistello, 2021, JAMA network open.

Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, A. Giannetti, 2020, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Mucosal cell populations may contribute to peripheral immune abnormalities in HIV-infected subjects introducing cART with moderate immune-suppression

A. d’Arminio Monforte, C. Tincati, G. Marchetti, 2019, PloS one.

Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment.

A. d’Arminio Monforte, A. Lazzarin, L. Calza, 2018, The new microbiologica.

Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus–infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study

A. Mocroft, A. d’Arminio Monforte, R. Weber, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HPV Infection in a Cohort of HIV-Positive Men and Women: Prevalence of Oncogenic Genotypes and Predictors of Mucosal Damage at Genital and Oral Sites

A. d’Arminio Monforte, S. Bosari, S. Romagnoli, 2013, Journal of sexually transmitted diseases.

CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.

A. d’Arminio Monforte, E. Nicastri, A. Antinori, 2015, The lancet. HIV.

Bacterial coinfections in dengue virus disease: what we know and what is still obscure about an emerging concern

A. d’Arminio Monforte, Ottavia Viganò, A. Savoldi, 2017, Infection.

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens

C. Leen, A. Mocroft, O. Kirk, 2017, HIV medicine.

Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry

A. d’Arminio Monforte, M. Zazzi, D. Francisci, 2020, Open forum infectious diseases.

Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study

A. d’Arminio Monforte, F. Lampe, A. De Luca, 2018, European Journal of Clinical Microbiology & Infectious Diseases.

Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort

A. d’Arminio Monforte, P. Cinque, F. Bai, 2017, PloS one.

Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study

Sally S Bebawy, Richard D Moore, J. Margolick, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients.

A. d’Arminio Monforte, V. Vullo, A. De Luca, 2015, The Journal of infectious diseases.

Reduced Central Memory CD4+ T Cells and Increased T-Cell Activation Characterise Treatment-Naive Patients Newly Diagnosed at Late Stage of HIV Infection

A. d’Arminio Monforte, F. Bai, C. Tincati, 2011, AIDS research and treatment.

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.

Ross J. Harris, J. Sterne, A. Mocroft, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy

A. d’Arminio Monforte, A. Lazzarin, M. Clerici, 2009, Infection.

Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/µl in the era of cART

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2008, Scandinavian journal of infectious diseases.

Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, A. Antinori, 2017, PloS one.

Multiple viral infections.

A. d’Arminio Monforte, P. Cicconi, A. Cozzi-Lepri, 2006, Journal of hepatology.

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus‐coinfected individuals in EuroSIDA

C. Leen, A. Mocroft, A. d’Arminio Monforte, 2019, HIV medicine.

Effect of changes in body mass index on the risk of cardiovascular disease and diabetes mellitus in HIV-positive individuals: results from the D: A: D study\.

A. Mocroft, A. d’Arminio Monforte, R. Weber, 2020, Journal of acquired immune deficiency syndromes.

Risk for Non–AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2021, Annals of Internal Medicine.

Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study

O. Kirk, A. d’Arminio Monforte, C. Sabin, 2013, BMC Infectious Diseases.

Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study

A. d’Arminio Monforte, D. Salmon, A. Cozzi-Lepri, 2016, HIV clinical trials.

Is the rate of virological failure to cART continuing to decline in recent calendar years?

A. d’Arminio Monforte, A. Antinori, A. Cingolani, 2019, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial

A. d’Arminio Monforte, V. Vullo, A. Antinori, 2017, PLoS ONE.

Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2013, The Journal of antimicrobial chemotherapy.

Life Expectancy in the Immune Recovery Era: The Evolving Scenario of the HIV Epidemic in Northern Italy

A. Roverato, C. Franceschi, A. d’Arminio Monforte, 2014, Journal of acquired immune deficiency syndromes.

Caring for women living with HIV: gaps in the evidence

A. d’Arminio Monforte, M. Johnson, M. Loutfy, 2013, Journal of the International AIDS Society.

Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts.

A. d’Arminio Monforte, P. Narciso, M. Capobianchi, 2012, The Journal of antimicrobial chemotherapy.

Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures.

A. d’Arminio Monforte, V. Vullo, A. Antinori, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999

A. Mocroft, F. Antunes, A. d’Arminio Monforte, 2008, HIV medicine.

One‐year cognitive follow‐up of COVID‐19 hospitalized patients

A. Priori, A. d’Arminio Monforte, R. Ferrucci, 2022, European journal of neurology.

Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord

O. Kirk, A. d’Arminio Monforte, M. Egger, 2014, AIDS.

Associations between serum albumin and serious non-AIDS events among people living with HIV

A. Mocroft, A. d’Arminio Monforte, R. Weber, 2018, AIDS.

Sudden cardiac death in a young HIV-positive man on effective antiretroviral therapy.

A. d’Arminio Monforte, C. Tincati, G. Marchetti, 2008, Current HIV research.

Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.

A. d’Arminio Monforte, A. Lazzarin, A. Antinori, 2018, The new microbiologica.

Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition.

A. d’Arminio Monforte, A. Antinori, A. De Luca, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients

A. d’Arminio Monforte, C. Tincati, G. Marchetti, 2013, Journal of Translational Medicine.

Do Combination Antiretroviral Therapy Regimens for HIV Infection Feature Diverse T-Cell Phenotypes and Inflammatory Profiles?

A. d’Arminio Monforte, F. Bai, D. Mondatore, 2020, Open forum infectious diseases.

Use of the FRAX equation as first-line screening of bone metabolism alteration in the HIV-infected population.

A. d’Arminio Monforte, A. Del Sole, A. Savoldi, 2010, Journal of Infectious Diseases.

A first update on mapping the human genetic architecture of COVID-19

Eurie L. Hong, E. F. Perez, Rachel G Liao, 2022, Nature.

Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study

O. Kirk, A. d’Arminio Monforte, R. Weber, 2016, Open forum infectious diseases.

Evidence for Polymicrobic Flora Translocating in Peripheral Blood of HIV-Infected Patients with Poor Immune Response to Antiretroviral Therapy

A. d’Arminio Monforte, F. Bai, C. Tincati, 2011, PloS one.

T-cell subsets and serum immunoglobulin levels in infants born to HIV-seropositive mothers: a longitudinal evaluation.

A. d’Arminio Monforte, N. Principi, M. Galli, 1990, AIDS.

Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen: Results from an Observational Cohort Study

A. d’Arminio Monforte, M. Magnani, C. Tincati, 2019, Clinical Drug Investigation.

Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients

A. d’Arminio Monforte, A. Antinori, G. Marchetti, 2018, HIV clinical trials.

HIV‐infected long‐term nonprogressors display a unique correlative pattern between the interleukin‐7/interleukin‐7 receptor circuit and T‐cell homeostasis

A. d’Arminio Monforte, M. Magnani, C. Mussini, 2009, HIV medicine.

Impact of daily versus weekly service of infectious diseases consultation on hospital antimicrobial consumption: a retrospective study

A. d’Arminio Monforte, Andrea Cona, Ottavia Viganò, 2020, BMC Infectious Diseases.

Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?

A. d’Arminio Monforte, F. Bai, A. Tavelli, 2020, International Journal of Infectious Diseases.

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens

Thi Huyen Tram Nguyen, A. d’Arminio Monforte, F. Ceccherini‐Silberstein, 2017, PloS one.

Hepatitis C management in prisons: An insight into daily clinical practice in three major Italian correctional houses

A. d’Arminio Monforte, A. Radice, R. Ranieri, 2016, Hepatology.

All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2012, International journal of epidemiology.

HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Cuomo, 2020, Open forum infectious diseases.

Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, The Journal of antimicrobial chemotherapy.

Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study.

M. Moroni, A. d’Arminio Monforte, E. Gianelli, 2002, Archives of internal medicine.

Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.

J. Sterne, O. Kirk, A. d’Arminio Monforte, 2012, International journal of epidemiology.

Brief Report: Soluble CD163 in CMV-Infected and CMV-Uninfected Subjects on Virologically Suppressive Antiretroviral Therapy in the ICONA Cohort

A. d’Arminio Monforte, V. Vullo, G. Marchetti, 2017, Journal of acquired immune deficiency syndromes.

Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities: is it time to assess the definitions?

A. d’Arminio Monforte, G. d’Ettorre, A. Antinori, 2019, AIDS.

Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population

A. d’Arminio Monforte, S. Hohaus, A. Antinori, 2017, PloS one.

Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study

A. d’Arminio Monforte, E. Buscarini, P. Lampertico, 2021, Hepatology communications.

Comparison of three therapeutic regimens for genotype‐3 hepatitis C virus infection in a large real‐life multicentre cohort

A. d’Arminio Monforte, S. Lazzaroni, M. Valsecchi, 2020, Liver international : official journal of the International Association for the Study of the Liver.

Increased incidence of sexually transmitted diseases in the recent years: data from the ICONA cohort

A. d’Arminio Monforte, A. Antinori, G. Guaraldi, 2014, Journal of the International AIDS Society.

Beyond Italian guidelines in the management of HIV-positive patient.

A. d’Arminio Monforte, A. Antinori, C. Mussini, 2020, Le infezioni in medicina.

Tuberculosis among European patients with the acquired immune deficiency syndrome. The AIDS in Europe Study Group.

A. d’Arminio Monforte, C. Katlama, J. Gatell, 1996, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count

A. d’Arminio Monforte, A. di Caro, A. Antinori, 2011, AIDS.

Short‐term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study

A. Mocroft, A. d’Arminio Monforte, J. Lundgren, 2016, HIV medicine.

Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis

A. d’Arminio Monforte, P. Messa, M. Falleni, 2019, International journal of molecular sciences.

Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results

A. d’Arminio Monforte, A. Lazzarin, A. Antinori, 2014, AIDS.

Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders

A. d’Arminio Monforte, A. Antinori, P. Cinque, 2012, AIDS research and treatment.

Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium.

A. Mocroft, A. d’Arminio Monforte, H. Günthard, 2022, The lancet. HIV.

Liver Enzyme Elevation During Darunavir-Based Antiretroviral Treatment in HIV-1–Infected Patients With or Without Hepatitis C Coinfection: Data from the ICONA Foundation Cohort

A. d’Arminio Monforte, A. Antinori, P. Lorenzini, 2014, HIV clinical trials.

Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series

A. d’Arminio Monforte, A. Winston, A. Antinori, 2021 .

Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.

O. Kirk, A. d’Arminio Monforte, R. Weber, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Predictive factors of vascular intima media thickness in HIV-positive subjects.

A. d’Arminio Monforte, P. Cicconi, T. Bini, 2007, The Journal of antimicrobial chemotherapy.

Cytokine and Chemokine Retention Profile in COVID-19 Patients with Chronic Kidney Disease

A. d’Arminio Monforte, G. Marchetti, M. Cozzolino, 2022, Toxins.

Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients.

J. Sterne, O. Kirk, A. d’Arminio Monforte, 2014, AIDS.

Reference curves for CD4 T‐cell count response to combination antiretroviral therapy in HIV‐1‐infected treatment‐naïve patients

A. Mocroft, A. d’Arminio Monforte, C. Sabin, 2017, HIV medicine.

Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study.

A. d’Arminio Monforte, V. Vullo, M. Capobianchi, 2012, Journal of acquired immune deficiency syndromes.

Sequencing of bacterial microflora in peripheral blood: our experience with HIV-infected patients.

A. d’Arminio Monforte, C. Tincati, G. Marchetti, 2011, Journal of visualized experiments : JoVE.

Association between SARS-CoV-2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID-19 patients

A. d’Arminio Monforte, A. Finzi, M. Augello, 2022, Scientific Reports.

A 20-year-old girl with an unusual febrile illness

A. d’Arminio Monforte, F. Bai, R. Castoldi, 2021, Internal and Emergency Medicine.

AIDS‐defining diseases in 250 HIV‐infected patients; a comparative study of clinical and autopsy diagnoses

M. Moroni, A. d’Arminio Monforte, A. Lazzarin, 1992, AIDS.

Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable disease with different outcome.

M. Moroni, A. d’Arminio Monforte, A. Monforte, 1985, The Journal of infectious diseases.

Reply to Manfredi

A. d’Arminio Monforte, M. Lichtner, S. Vita, 2014, The Journal of infectious diseases.

Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium.

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2021, The lancet. HIV.

Nephrolithiasis and hydronephrosis in an HIV-infected man receiving tenofovir.

A. d’Arminio Monforte, P. Cicconi, T. Bini, 2004, International journal of antimicrobial agents.

Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice

A. d’Arminio Monforte, A. Antinori, G. di Perri, 2016, PloS one.

Response to combination antiretroviral therapy: variation by age

A. d’Arminio Monforte, C. Sabin, M. Battegay, 2008, AIDS.

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, A. Antinori, 2017, PloS one.

Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study.

A. d’Arminio Monforte, A. Lazzarin, P. Viale, 2014, The new microbiologica.

Growth Differentiation Factor 15 (GDF-15) Levels Associate with Lower Survival in Chronic Kidney Disease Patients with COVID-19

A. d’Arminio Monforte, C. Tincati, G. Marchetti, 2022, Biomedicines.

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

O. Kirk, A. d’Arminio Monforte, R. Weber, 2008, The Lancet.

Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990-2014.

A. d’Arminio Monforte, R. Geskus, M. Prins, 2017, Journal of hepatology.

Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2015, Liver international : official journal of the International Association for the Study of the Liver.

A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study.

A. Mocroft, O. Kirk, A. Blaxhult, 2002, The Journal of infectious diseases.

Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

J. Sterne, A. Mocroft, A. d’Arminio Monforte, 2016, International journal of epidemiology.

Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study.

A. d’Arminio Monforte, J. Miro, A. Lazzarin, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co‐infected HIV patients with cirrhosis

A. d’Arminio Monforte, D. Raben, F. Dabis, 2019, Journal of viral hepatitis.

Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs

Richard D Moore, K. Anastos, O. Kirk, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).

J. Sterne, A. Mocroft, A. d’Arminio Monforte, 2014, International journal of epidemiology.

The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.

B. Gazzard, A. Mocroft, O. Kirk, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Coding Causes of Death in HIV (CoDe) Project: Initial Results and Evaluation of Methodology

J. Sterne, A. Mocroft, O. Kirk, 2011, Epidemiology.

An outbreak of delta agent among a group of drug addicts and their close contacts.

A. d’Arminio Monforte, P. Farci, F. Caredda, 1984, The Journal of infectious diseases.

Indicator disease‐guided testing for HIV – the next step for Europe?

B. Gazzard, A. d’Arminio Monforte, J. Lundgren, 2008, HIV medicine.

Effect of zidovudine in HIV-infected children with lymphocytic interstitial pneumonitis.

A. d’Arminio Monforte, N. Principi, A. Plebani, 1991, AIDS.

Indinavir-related alopecia.

A. d’Arminio Monforte, A. Gori, T. Bini, 1998, AIDS.

Zygomycosis in Italy: A Survey of FIMUA-ECMM (Federazione Italiana Di Micopatologia Umana ed Animale and European Confederation of Medical Mycology)

C. Romano, A. d’Arminio Monforte, L. Pagano, 2009, Journal of chemotherapy.

Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.

M. Moroni, A. d’Arminio Monforte, A. Antinori, 2000, The Journal of infectious diseases.

Early diagnosis of HIV infection in infants.

A. d’Arminio Monforte, A. Lazzarin, N. Principi, 1989, AIDS.

Autoantibody pattern in non-A, non-B hepatitis

A. d’Arminio Monforte, L. Zampini, P. Meroni, 1984, Infection.

The aetiology of acute hepatitis in Zimbabwe.

A. d’Arminio Monforte, P. Farci, S. Cenzuales, 1984, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Unconventional T cells in chronic hepatitis B patients on long‐term suppressive therapy with tenofovir followed by a Peg‐IFN add‐on strategy: A randomized study

A. d’Arminio Monforte, S. Antinori, C. Tincati, 2018, Journal of viral hepatitis.

Foscarnet treatment of chronic hepatitis B in an HIV-positive patient.

M. Moroni, A. d’Arminio Monforte, S. Antinori, 1993, Journal of hepatology.

Recent Acquired STD and the Use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): Analysis of the Incidence of Newly Acquired Hepatitis B Infection and Syphilis

A. d’Arminio Monforte, C. Tincati, F. T. P. Group, 2008, Infection.

Occult hepatitis B virus infection in a Cohort of HIV-positive patients: Correlation with hepatitis C virus coinfection, virological and immunological features

A. d’Arminio Monforte, A. Lazzarin, D. Santoro, 2009, Infection.

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis

Jonathan A C Sterne, Matthias Egger, Caroline A Sabin, 2006, The Lancet.

Observational Study on HIV-Infected Subjects Failing HAART Receiving Tenofovir Plus Didanosine as NRTI Backbone

A. d’Arminio Monforte, C. Mussini, P. Cicconi, 2007, Infection.

First‐line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, A. Lazzarin, 2018, HIV medicine.

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016.

A. d’Arminio Monforte, A. Lazzarin, A. Antinori, 2017, The new microbiologica.

Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution.

Valentina Svicher, Jens Verheyen, Valeria Micheli, 2013, The Journal of general virology.

Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed.

Alessandro Cozzi-Lepri, A. d’Arminio Monforte, C. Perno, 2004, The Journal of infectious diseases.

Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy.

Fulvio Adorni, Cristina Gervasoni, Mauro Vaccarezza, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hepatitis delta in HIV-infected individuals in Europe

C. Leen, F. Antunes, A. d’Arminio Monforte, 2011, AIDS.

Management of Chronic Hepatitis B in HIV-Coinfected Patients

A. d’Arminio Monforte, S. Lo Caputo, T. Santantonio, 2022, Viruses.

Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects.

A. d’Arminio Monforte, A. Antinori, A. De Luca, 2002, Archives of internal medicine.

Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis.

A. d’Arminio Monforte, A. Antinori, A. De Luca, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prospective study of epidemic delta infection in drug addicts.

M. Moroni, A. d’Arminio Monforte, P. Farci, 1983, Progress in clinical and biological research.

Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral‐naïve patients

A Cozzi-Lepri, A. d’Arminio Monforte, P. Cicconi, 2010, HIV medicine.

Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study.

A. d’Arminio Monforte, G. Ippolito, P. Pezzotti, 2002, Acta psychiatrica Scandinavica.

New-onset delusions and hallucinations in patients infected with HIV.

A. d’Arminio Monforte, A. Monforte, A. Alciati, 2001, Journal of psychiatry & neuroscience : JPN.

Evolution of major non‐HIV‐related comorbidities in HIV‐infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014

A. d’Arminio Monforte, A. De Luca, G. Guaraldi, 2018, HIV medicine.

Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study

A. d’Arminio Monforte, A. Lazzarin, A. Antinori, 2014, Journal of the International AIDS Society.

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.

M. Moroni, A. d’Arminio Monforte, A. Lazzarin, 2011, The new microbiologica.

Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy

A. d’Arminio Monforte, A. Antinori, A. De Luca, 2016, Journal of acquired immune deficiency syndromes.

Italian consensus statement on paediatric HIV infection

A. d’Arminio Monforte, C. Giaquinto, R. Badolato, 2010, Infection.

HIV-Infected Late Presenter Patients

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, J. Montaner, 2011, AIDS research and treatment.

Declining Incidence of AIDS and Increasing Prevalence of AIDS Presenters Among AIDS Patients in Italy

A. d’Arminio Monforte, B. Castelnuovo, P. Cicconi, 2003, European Journal of Clinical Microbiology and Infectious Diseases.

Estimating duration of HIV infection with CD4 cell count and HIV-1 RNA at presentation.

A. d’Arminio Monforte, G. Ippolito, D. Serraino, 2001, AIDS.

Women Facing HIV. Key Question on Women with HIV Infection: Italian Consensus Workshop

A. d’Arminio Monforte, E. Ferrazzi, F. Mazzotta, 2009, Infection.

Modelling the 3‐year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti‐HIV Drugs (DAD) study

O. Kirk, A. d’Arminio Monforte, J. Lundgren, 2003, HIV medicine.

The impact of DAA‐mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, A. Antinori, 2021, Journal of viral hepatitis.

Mapping the human genetic architecture of COVID-19

Mattia G. Bergomi, Christopher M. DeBoever, Matthew A. Wiles, 2021, Nature.

Dyslipidaemia after switch to tenofovir alafenamide (TAF)‐based cART regimens in a cohort of HIV‐positive patients: what clinical relevance?

A. d’Arminio Monforte, D. Mondatore, G. Tagliaferri, 2020, HIV medicine.

Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy

J. Sterne, A. d’Arminio Monforte, F. Lampe, 2016, PloS one.

Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies

J. Sterne, A. d’Arminio Monforte, M. Egger, 2003, The Lancet.

When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study

M. Moroni, A. d’Arminio Monforte, A. Phillips, 2001, AIDS.

Evaluation of glomerular filtration rate in HIV‐1‐infected patients before and after combined antiretroviral therapy exposure *

A. d’Arminio Monforte, A. De Luca, A. Gori, 2011, HIV medicine.

Induced first abortion rates before and after HIV diagnosis: results of an Italian self‐administered questionnaire survey carried out in 585 women living with HIV

A. d’Arminio Monforte, G. d’Ettorre, P. Cicconi, 2013, HIV medicine.

A. d’Arminio Monforte, R. Talamini, F. Chiodo, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort.

A. d’Arminio Monforte, P. Lorenzini, N. Abrescia, 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Prevalence of Chagas disease and strongyloidiasis among HIV-infected Latin American immigrants in Italy - The CHILI study.

A. d’Arminio Monforte, E. Nicastri, P. Rodari, 2022, Travel medicine and infectious disease.

Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy.

A. d’Arminio Monforte, A. Antinori, P. Cinque, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Psychological outcomes after hospitalization for COVID-19: data from a multidisciplinary follow-up screening program for recovered patients

A. d’Arminio Monforte, F. Bai, Kyrie Piscopo, 2020, Research in psychotherapy.

Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART)

A. d’Arminio Monforte, F. Bai, G. Marchetti, 2018, Journal of NeuroVirology.

Prevalence of transfusion-transmitted virus among human immunodeficiency virus-infected subjects in northern Italy.

A. d’Arminio Monforte, A. Lobbiani, L. Sciariada, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Association Between Impaired Vα7.2+CD161++CD8+ (MAIT) and Vα7.2+CD161-CD8+ T-Cell Populations and Gut Dysbiosis in Chronically HIV- and/or HCV-Infected Patients

P. Klenerman, A. d’Arminio Monforte, Leo Swadling, 2019, Front. Microbiol..

Successful direct‐acting antiviral therapy in HIV/HCV co‐infected patients fails to restore circulating mucosal‐associated invariant T cells

P. Klenerman, A. d’Arminio Monforte, Leo Swadling, 2019, European journal of immunology.

ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population

A. d’Arminio Monforte, G. Matullo, R. Scala, 2020, European Journal of Human Genetics.

Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2018, The Journal of antimicrobial chemotherapy.

Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, BMC Public Health.

Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, A. Antinori, 2019, Journal of the International AIDS Society.

Changes in hospital admissions across Europe: 1995–2003. Results from the EuroSIDA study

A. Mocroft, O. Kirk, A. Blaxhult, 2004, HIV medicine.

Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.

Ross J. Harris, M. Zwahlen, A. d’Arminio Monforte, 2009, International journal of epidemiology.

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

Karin J. Metzner, Huldrych F. Günthard, E. Nicastri, 2014, The Journal of antimicrobial chemotherapy.

Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study☆

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2019, EClinicalMedicine.

Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies

J. Sterne, A. d’Arminio Monforte, M. Egger, 2007, AIDS.

Evaluation of the effect of protective genetic variants on cART success in HIV-1-infected patients.

A. d’Arminio Monforte, M. Clerici, A. Tavelli, 2020, Journal of biological regulators and homeostatic agents.

Increased risk of cardiovascular disease (CVD) with age in HIV‐positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations

O. Kirk, A. d’Arminio Monforte, J. Lundgren, 2014, HIV medicine.

Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2001 .

Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study

J. Sterne, A. d’Arminio Monforte, P. Reiss, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV‐positive persons: the Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) study

O. Kirk, A. d’Arminio Monforte, C. Sabin, 2018, HIV medicine.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Chest pain and a left parasternal soft tissue swelling in an immunocompetent refugee with disseminated tuberculosis.

A. d’Arminio Monforte, Ottavia Viganò, S. Carugo, 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative to ART-CC Cohort Study

Ross J. Harris, R. Haubrich, J. Sterne, 2011, Journal of acquired immune deficiency syndromes.

Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries

B. Chi, J. Sterne, K. Anastos, 2013, Journal of acquired immune deficiency syndromes.

Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study.

M. Moroni, A. d’Arminio Monforte, A. Phillips, 2002, The Journal of infectious diseases.

The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis

O. Kirk, A. d’Arminio Monforte, R. Weber, 2012, HIV medicine.

Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation

A. d’Arminio Monforte, A. Antinori, P. Lorenzini, 2017, AIDS Patients Care and STDs.

Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort

A. d’Arminio Monforte, A. Antinori, A. De Luca, 2014, Journal of the International AIDS Society.

Free light chains and the risk of nonmalignant AIDS events in HIV-infected patients treated with combination antiretroviral therapy.

A. d’Arminio Monforte, A. Antinori, M. Bibas, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Persistence of High Percentage of Peripheral Activated CD8+ T Cells Predict Cytologic HPV-Related Dysplasia in cART-Treated, HIV-Positive Subjects

A. d’Arminio Monforte, F. Bai, M. Augello, 2022, Open forum infectious diseases.

Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome–related Kaposi sarcoma

A. d’Arminio Monforte, R. Talamini, U. Tirelli, 2003, Cancer.

Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients

Andrea Giacometti, Laura Milazzo, Giustino Parruti, 2018, PloS one.

Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study

A. d’Arminio Monforte, T. Hallett, A. Mammone, 2017, PloS one.

Pregnancy Outcomes Among ART-Naive and ART-Experienced HIV-Positive Women: Data From the ICONA Foundation Study Group, Years 1997–2013

A. d’Arminio Monforte, A. Cingolani, S. Lo Caputo, 2014, Journal of acquired immune deficiency syndromes.

Incidence, Timing, and Determinants of Bacterial Pneumonia Among HIV-Infected Patients: Data From the ICONA Foundation Cohort

A. d’Arminio Monforte, A. Antinori, A. De Luca, 2013, Journal of acquired immune deficiency syndromes.

Polymerase chain reaction for Toxoplasma gondii DNA in the cerebrospinal fluid of AIDS patients with focal brain lesions

A. d’Arminio Monforte, A. Lazzarin, A. Castagna, 1994, AIDS.

The Management of Geriatric and Frail HIV Patients. A 2017 Update from the Italian Guidelines for the Use of Antiretroviral Agents and the Diagnostic-Clinical Management of HIV-1 Infected Persons

C. Mussi, M. Cesari, A. d’Arminio Monforte, 2018, The Journal of Frailty & Aging.

Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV

A. d’Arminio Monforte, A. Antinori, P. Lorenzini, 2017, Journal of acquired immune deficiency syndromes.

Subclinical hypothyroidism in HIV-infected subjects.

A. d’Arminio Monforte, C. Tincati, P. Cicconi, 2006, The Journal of antimicrobial chemotherapy.

Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2012, AIDS.

Role of serum free light chains in predicting HIV‐associated non‐Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy

A. d’Arminio Monforte, A. di Caro, A. Antinori, 2012, American journal of hematology.

The EuroSIDA study: 25 years of scientific achievements

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2019, HIV medicine.

Increases in acute hepatitis C (HCV) incidence across Europe: which regions and patient groups are affected?

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2012 .

The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.

J. Sterne, A. d’Arminio Monforte, M. Egger, 2005, Archives of internal medicine.

Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts.

A. d’Arminio Monforte, C. Mussini, A. Cingolani, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Access to gynecological services and Papanicolau tests in HIV-infected Italian women: A questionnaire survey

S. Franceschi, A. d’Arminio Monforte, G. Ippolito, 2006, AIDS care.

Less drug regimens and PI/r-based strategies in HIV infection: focus on best practices using the HIV patient's journey methodology.

A. d’Arminio Monforte, G. Ippolito, A. Lazzarin, 2014, The new microbiologica.

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015.

A. d’Arminio Monforte, A. Lazzarin, A. Antinori, 2016, The new microbiologica.

Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+ : CD8+ ratio

J. Sterne, A. d’Arminio Monforte, P. Reiss, 2018, AIDS.

Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)

A. d’Arminio Monforte, C. Agrati, E. Nicastri, 2023, eClinicalMedicine.

Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?

O. Kirk, A. d’Arminio Monforte, F. van Leth, 2004, The Journal of infectious diseases.

Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America.

J. Sterne, O. Kirk, A. d’Arminio Monforte, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

CD8 T-Cell Activation Is Associated With Lipodystrophy and Visceral Fat Accumulation in Antiretroviral Therapy–Treated Virologically Suppressed HIV-Infected Patients

A. d’Arminio Monforte, G. Guaraldi, J. Capeau, 2013, Journal of acquired immune deficiency syndromes.

Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research

S. Ceri, A. d’Arminio Monforte, P. Pinoli, 2021, European Journal of Human Genetics.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Characterization and Structural Analysis of Novel Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involved in the Regulation of Resistance to Nonnucleoside Inhibitors

Thomas Lengauer, Stefano Alcaro, Jan Balzarini, 2007, Journal of Virology.

Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors

Thomas Lengauer, A. d’Arminio Monforte, F. Ceccherini‐Silberstein, 2006, Journal of Virology.

Cerebral astrocytoma in HIV-infected patients.

A. d’Arminio Monforte, L. Vago, C. Gervasoni, 1995, AIDS.

Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study

A. d’Arminio Monforte, A. Antinori, A. Cingolani, 2021, Viruses.

Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

A. Mocroft, A. d’Arminio Monforte, A. Clarke, 2018, HIV medicine.

Efavirenz-containing highly active antiretroviral therapy in an HIV-infected patient with myasthenia gravis.

A. d’Arminio Monforte, T. Bini, S. Melzi, 2003, AIDS.

Awareness and perception of accuracy of the Undetectable=Untransmittable message (U=U) in Italy: results from a survey among PLWHA, infectious-diseases physicians and people having unprotected sex

A. d’Arminio Monforte, A. Antinori, A. Cingolani, 2022, AIDS care.

A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations

C. Morrison, P. Vanhems, A. Kamali, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The importance of patients’ case-mix for the correct interpretation of the hospital fatality rate in COVID-19 disease

A. d’Arminio Monforte, F. Bai, D. Tomasoni, 2020, International Journal of Infectious Diseases.

Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort

A. d’Arminio Monforte, A. Antinori, G. Guaraldi, 2015, HIV medicine.

Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study

A. Grzeszczuk, M. L. Jakobsen, J. Minton, 2015, PloS one.

Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants.

K. Metzner, A. d’Arminio Monforte, A. Schultze, 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

An explainable model of host genetic interactions linked to COVID-19 severity

G. Parati, A. d’Arminio Monforte, F. Chiaromonte, 2021, Communications Biology.

Protease inhibitors and erectile dysfunction.

A. d’Arminio Monforte, M. Zucconi, A. Alciati, 2001, AIDS.

Legionnaires' disease contracted from patient workplace: First report of a severe case of coinfection with varicella-zoster virus.

A. d’Arminio Monforte, M. Faccini, S. Fontana, 2016, American journal of infection control.

Survival Outcomes and Effect of Early vs. Deferred cART Among HIV-Infected Patients Diagnosed at the Time of an AIDS-Defining Event: A Cohort Analysis

A. d’Arminio Monforte, C. Sabin, J. Miro, 2011, PloS one.

Changing incidence of central nervous system diseases in the EuroSIDA cohort

A. Mocroft, O. Kirk, F. Antunes, 2004, Annals of neurology.

What do the changing patterns of comorbidity burden in people living with HIV mean for long‐term management? Perspectives from European HIV cohorts

A. d’Arminio Monforte, N. Pantazis, E. Wolf, 2020, HIV medicine.

Microglial nodular encephalitis and ventriculoencephalitis due to cytomegalovirus infection in patients with AIDS: two distinct clinical patterns.

M. Grassi, A. d’Arminio Monforte, F. Clerici, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The use of the Framingham equation to predict myocardial infarctions in HIV‐infected patients: comparison with observed events in the D:A:D Study

O. Kirk, A. d’Arminio Monforte, J. Lundgren, 2006, HIV medicine.

Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy

A. d’Arminio Monforte, P. Lorenzini, C. Mussini, 2018, BMC Public Health.

Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness

A. d’Arminio Monforte, R. Badolato, C. Tincati, 2020, Frontiers in Immunology.

Antiretroviral pill count and clinical outcomes in treatment‐naïve patients with HIV infection

A. d’Arminio Monforte, P. Reiss, M. Saag, 2018, HIV medicine.

Multi-Criteria Decision Analysis to prioritize hospital admission of patients affected by COVID-19 in low-resource settings with hospital-bed shortage

H. Goossens, G. Malerba, A. d’Arminio Monforte, 2020, International Journal of Infectious Diseases.

Reorienting health systems to care for people with HIV beyond viral suppression.

A. d’Arminio Monforte, J. Lazarus, N. Azzopardi-Muscat, 2019, The lancet. HIV.

Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)

A. d’Arminio Monforte, F. Bai, G. Marchetti, 2020, Expert review of anti-infective therapy.

Parameter estimates for trends and patterns of excess mortality among persons on antiretroviral therapy in high-income European settings

J. Sterne, A. d’Arminio Monforte, M. Gill, 2019, AIDS.

An international perspective on hospitalized patients with viral community-acquired pneumonia

W. Rodriguez-Cintron, J. Vincent, A. d’Arminio Monforte, 2018, European journal of internal medicine.

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2018, BMC Medicine.

Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIV

A. Mocroft, A. d’Arminio Monforte, H. Günthard, 2022, AIDS.

Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study

O. Kirk, A. d’Arminio Monforte, R. Weber, 2010, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The “STORE” Study

A. d’Arminio Monforte, R. Maserati, A. Antinori, 2020, Journal of acquired immune deficiency syndromes.

CD4 cell counts at the third month of HAART may predict clinical failure.

A. d’Arminio Monforte, B. Castelnuovo, M. Musicco, 1999, AIDS.

Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study

A. d’Arminio Monforte, G. Ippolito, P. Pezzotti, 2002 .

CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 × 106 cells/l

A. d’Arminio Monforte, A. Antinori, A. De Luca, 2005, AIDS.

Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998–2008

A. d’Arminio Monforte, A. De Luca, C. Torti, 2011, HIV medicine.

thology in the laryngeal abductor muscle. The mechanism of LS could contribute to heterogenous physiologic and pathologic le- sions of the central and peripheral nervous system in MSA

A. d’Arminio Monforte, R. Murri, A. Ammassari, 2003 .

Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1–Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy

J. Sterne, A. d’Arminio Monforte, P. Reiss, 2018, Journal of acquired immune deficiency syndromes.

Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study.

A. d’Arminio Monforte, P. Narciso, A. Antinori, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Differences in clinical characteristics and quantitative lung CT features between vaccinated and not vaccinated hospitalized COVID-19 patients in Italy

A. d’Arminio Monforte, A. Tavelli, G. Marchetti, 2023, Annals of Intensive Care.

Evolution of HIV-1 transmitted drug resistance in Italy in the 2007-2014 period: A weighted analysis.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, E. Nicastri, 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

Ross J. Harris, J. Sterne, A. d’Arminio Monforte, 2008, AIDS.

A comparison of estimated glomerular filtration rates using Cockcroft−Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2013, HIV Medicine.

HIV Clinical Pathway: A New Approach to Combine Guidelines and Sustainability of Anti-Retroviral Treatment in Italy

A. d’Arminio Monforte, A. Lazzarin, E. Foglia, 2016, PloS one.

Long-Term Suppressive cART Is Not Sufficient to Restore Intestinal Permeability and Gut Microbiota Compositional Changes

A. d’Arminio Monforte, F. Bai, M. Augello, 2021, Frontiers in Immunology.

Long-Lasting Cognitive Abnormalities after COVID-19

A. Priori, A. d’Arminio Monforte, R. Ferrucci, 2021, Brain sciences.

Stimulation of PBMC and Monocyte-Derived Macrophages via Toll-Like Receptor Activates Innate Immune Pathways in HIV-Infected Patients on Virally Suppressive Combination Antiretroviral Therapy

A. d’Arminio Monforte, M. Clerici, A. Cappione, 2016, Front. Immunol..

Illness Representations of HIV Positive Patients Are Associated with Virologic Success

A. d’Arminio Monforte, E. Vegni, D. Leone, 2016, Front. Psychol..

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014.

A. d’Arminio Monforte, A. Lazzarin, A. Antinori, 2015, The new microbiologica.

Treatment interruptions in HIV-infected subjects.

A. d’Arminio Monforte, C. Tincati, M. Casana, 2006, The Journal of antimicrobial chemotherapy.

European AIDS Clinical Society Second Standard of Care Meeting, Brussels 16‐17 November 2016: a summary

A. d’Arminio Monforte, J. Lundgren, M. Battegay, 2018, HIV medicine.

Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients

A. d’Arminio Monforte, H. Günthard, E. Bernasconi, 2019, Open forum infectious diseases.

Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE

M. Zwahlen, A. Mocroft, O. Kirk, 2020, Clinical Infectious Diseases.

Withholding primary PcP prophylaxis in virologically suppressed HIV patients: An emulation of a pragmatic trial in COHERE.

J. Carpenter, M. Zwahlen, A. Mocroft, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature

A. d’Arminio Monforte, C. Tincati, G. Marchetti, 2018, BMC Infectious Diseases.

Immunological mechanisms of interleukin-2 (IL-2) treatment in HIV/AIDS disease.

A. d’Arminio Monforte, C. Tincati, G. Marchetti, 2009, Current molecular pharmacology.

An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project.

A. d’Arminio Monforte, R. Bruno, A. Lazzarin, 2015, The new microbiologica.

Medication adherence among HIV+ adults: Effects of cognitive dysfunction and regimen complexity

A. d’Arminio Monforte, R. Murri, A. Ammassari, 2003, Neurology.

Cost‐effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States

A. Mocroft, A. d’Arminio Monforte, R. Weber, 2021, Journal of the International AIDS Society.

Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART.

A. d’Arminio Monforte, A. Antinori, P. Lorenzini, 2016, The Journal of antimicrobial chemotherapy.

Comorbidities and HCV coinfection in the management of HIV+ patients: evidence from the Italian clinical practice

A. d’Arminio Monforte, E. Foglia, L. Ferrario, 2020, Health Economics Review.

Efficacy and Safety of Darunavir/Ritonavir Plus Etravirine Dual Regimen in Antiretroviral Therapy–Experienced Patients: A Multicenter Clinical Experience

A. d’Arminio Monforte, G. Marchetti, P. Cicconi, 2014, HIV clinical trials.

Non-nucleoside-reverse-transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects.

A. d’Arminio Monforte, F. Sardanelli, A. Fausto, 2006, The Journal of antimicrobial chemotherapy.

Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study

A. Mocroft, A. d’Arminio Monforte, R. Weber, 2014, Journal of the International AIDS Society.

Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers

A. d’Arminio Monforte, D. Tomasoni, A. Tavelli, 2021, EClinicalMedicine.

Decreasing incidence of CNS AIDS-defining events associated with antiretroviral therapy

M. Moroni, M. Grassi, A. d’Arminio Monforte, 2000, Neurology.

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients

A. d’Arminio Monforte, C. Fagard, F. Bai, 2010, AIDS.

Avascular necrosis of the femoral head in a HIV-1 infected patient receiving lopinavir/ritonavir.

A. d’Arminio Monforte, A. Riva, T. Bini, 2003, International journal of antimicrobial agents.

CMV co‐infection and risk of AIDS and non‐AIDS events in a large cohort of HIV‐infected patients

A. d’Arminio Monforte, V. Vullo, A. De Luca, 2012 .

Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, A. Antinori, 2020, Viruses.

Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy.

A. d’Arminio Monforte, L. Papagno, M. Clerici, 1998, AIDS.

Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART)

A. d’Arminio Monforte, F. Bai, G. Marchetti, 2018, Journal of NeuroVirology.

The contribution of late HIV diagnosis on the occurrence of HIV-associated tuberculosis

A. d’Arminio Monforte, C. Mussini, B. Castelnuovo, 2022, AIDS.

The Many Faces of Covid-19 at a Glance: A University Hospital Multidisciplinary Account From Milan, Italy

F. Biglioli, A. Priori, A. d’Arminio Monforte, 2021, Frontiers in Public Health.

Reduced HIV symptoms and improved health-related quality of life correlate with better access to care for HIV-1 infected women: the ELLA study

A. d’Arminio Monforte, R. Baran, I. Krznaric, 2014, Journal of the International AIDS Society.

Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, A. Antinori, 2014, Journal of the International AIDS Society.

Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir–Ritonavir Plus Either Raltegravir or Tenofovir–Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial

H. Amièva, A. d’Arminio Monforte, A. Winston, 2017, Journal of acquired immune deficiency syndromes.

Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2019, The Journal of Infectious Diseases.

Use of contemporary protease inhibitors and risk of incident chronic kidney disease in HIV-positive persons; the D:A:D Study.

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2019, The Journal of infectious diseases.

Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets

A. d’Arminio Monforte, D. Tesoro, C. Tincati, 2019, BMC Infectious Diseases.

Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy

A. d’Arminio Monforte, A. Gori, C. Mastroianni, 2015, PloS one.

A. Mocroft, A. d’Arminio Monforte, J. Lundgren, 2004 .

A Quantitative Estimate of the Expected Shortening of the Median Isolation Period of Patients With COVID-19 After the Adoption of a Symptom-Based Strategy

A. d’Arminio Monforte, F. Bai, D. Tomasoni, 2021, Frontiers in Public Health.

HBV or HCV Coinfections and Risk of Myocardial Infarction in HIV-Infected Individuals: The D:A:D Cohort Study

O. Kirk, A. d’Arminio Monforte, R. Weber, 2010, Antiviral therapy.

Contribution of alcohol use in HIV/hepatitis C virus co-infection to all-cause and cause-specific mortality: A collaboration of cohort studies.

J. Sterne, A. d’Arminio Monforte, C. Rentsch, 2023, Journal of viral hepatitis.

Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss

A. d’Arminio Monforte, A. Mammone, A. Antinori, 2021, Scientific Reports.

Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study – 2012 – 2015

B. Gazzard, A. Mocroft, A. d’Arminio Monforte, 2019, PloS one.

Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies.

J. Sterne, A. d’Arminio Monforte, M. Egger, 2023, The lancet. HIV.

Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort

A. d’Arminio Monforte, P. Lorenzini, N. Abrescia, 2014, Journal of the International AIDS Society.

HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients

A. d’Arminio Monforte, M. Capobianchi, M. Shanyinde, 2018, PloS one.

Role of In Vitro Stimulation with Lipopolysaccharide on T-Cell Activation in HIV-Infected Antiretroviral-Treated Patients

A. d’Arminio Monforte, C. Tincati, G. Marchetti, 2012, Clinical & developmental immunology.

Assessment of radiological vertebral fractures in HIV‐infected patients: clinical implications and predictive factors

A. d’Arminio Monforte, F. Bai, G. Marchetti, 2015, HIV medicine.

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study

A. d’Arminio Monforte, V. Vullo, M. Colafigli, 2019, Journal of acquired immune deficiency syndromes.

Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group

A. d’Arminio Monforte, F. Baldanti, F. Ceccherini‐Silberstein, 2013, Infection.

Ability to Monitor National Responses to the HIV Epidemic “Beyond Viral Suppression”: Findings From Six European Countries

A. d’Arminio Monforte, J. Lazarus, N. Azzopardi-Muscat, 2020, Frontiers in Public Health.

Sharp drop in the prevalence of human cytomegalovirus leuko-DNAemia in HIV-infected patients following highly active antiretroviral therapy.

A. d’Arminio Monforte, G. Gerna, M. Zavattoni, 1998, AIDS.

Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease.

A. d’Arminio Monforte, R. Bruno, A. Lazzarin, 2014, The new microbiologica.

Brief Report: Drop in CD4+ Counts Below 200 Cells/&mgr;L After Reaching (or Starting From) Values Higher than 350 Cells/&mgr;L in HIV-Infected Patients With Virological Suppression

A. d’Arminio Monforte, A. Antinori, C. Mussini, 2017, Journal of acquired immune deficiency syndromes.

Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, K. Theys, 2013, The Journal of antimicrobial chemotherapy.

Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART.

A. d’Arminio Monforte, P. Cicconi, A. di Biagio, 2005, The Journal of antimicrobial chemotherapy.

Six-month immune responses to mRNA-1273 vaccine in combination antiretroviral therapy treated late presenter people with HIV according to previous SARS-CoV-2 infection

A. d’Arminio Monforte, M. Augello, C. Tincati, 2023, AIDS.

Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV.

R. Haubrich, C. Leen, A. Mocroft, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Declining Mortality Rate of Hospitalised Patients in the Second Wave of the COVID-19 Epidemics in Italy: Risk Factors and the Age-Specific Patterns

A. d’Arminio Monforte, F. Bai, D. Tomasoni, 2021, Life.

Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort*

A. d’Arminio Monforte, A. Antinori, P. Lorenzini, 2018, HIV clinical trials.

Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort

Giuliano Rizzardini, Alessandro Cozzi-Lepri, Andrea De Luca, 2016, PloS one.

CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus

Anne M Johnson, C. Morrison, P. Vanhems, 2017, The Journal of antimicrobial chemotherapy.

Detection of Asymptomatic Mpox Carriers among High-Ri Men Who Have Sex with Men: A Prospective Analysis

A. d’Arminio Monforte, G. Mulé, A. Tavelli, 2023, Pathogens.

Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects

A. d’Arminio Monforte, M. Augello, C. Tincati, 2022, Viruses.

Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting

A. d’Arminio Monforte, A. Antinori, G. Marchetti, 2019, The Journal of antimicrobial chemotherapy.

Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection

M. Hernán, A. d’Arminio Monforte, C. Rentsch, 2022, Journal of the International AIDS Society.

Three case reports of West Nile virus neuroinvasive disease: lessons from real-life clinical practice

A. d’Arminio Monforte, D. Tomasoni, Camilla Falcinella, 2021, BMC Infectious Diseases.

A Comparison of Three Computational Modelling Methods for the Prediction of Virological Response to Combination Hiv Therapy Author's Personal Copy

Brendan Larder, Dechao Wang, Lidia Ruiz, 2022 .

Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV

A. Mocroft, A. d’Arminio Monforte, C. Sabin, 2023, Cancers.

Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens.

A. d’Arminio Monforte, R. Maserati, A. Lazzarin, 2013, The new microbiologica.

Combination antiretroviral therapy and the risk of myocardial infarction.

O. Kirk, A. d’Arminio Monforte, R. Weber, 2003, The New England journal of medicine.

HIV encephalitis and HIV leukoencephalopathy are associated with distinct clinical and radiological subtypes of the AIDS dementia complex.

M. Grassi, A. d’Arminio Monforte, F. Clerici, 1997, AIDS (London).

Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.

A. d’Arminio Monforte, A. Lazzarin, A. Antinori, 2016, The Journal of antimicrobial chemotherapy.

Diagnosis of Virus‐associated Opportunistic Diseases of the Central Nervous System in Patients with HIV Infection by Polymerase Chain Reaction on Cerebrospinal Fluid

A. d’Arminio Monforte, A. Lazzarin, P. Cinque, 1994, Annals of the New York Academy of Sciences.

Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study

W. Rodriguez-Cintron, A. d’Arminio Monforte, P. Koul, 2020, European Journal of Clinical Microbiology and Infectious Diseases.

Optimizing HIV therapy. A consensus project on differences between cytidine analogues and regime compactness.

A. d’Arminio Monforte, R. Maserati, A. Antinori, 2014, The new microbiologica.

Early Antiretroviral Therapy Not Associated With Higher Cryptococcal Meningitis Mortality in People With Human Immunodeficiency Virus in High-Income Countries: An International Collaborative Cohort Study

J. Sterne, A. Mocroft, A. d’Arminio Monforte, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Mapping the human genetic architecture of COVID-19

Mattia G. Bergomi, Christopher M. DeBoever, Matthew A. Wiles, 2021, Nature.

HIV-Indicator Condition Guided Testing in a Hospital Setting

A. d’Arminio Monforte, D. Barbanotti, C. Tincati, 2023, Life.

Mapping the human genetic architecture of COVID-19

Eurie L. Hong, E. F. Perez, Rachel G Liao, 2021 .

Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV‐positive persons version 9.0

S. McCormack, A. Mocroft, O. Kirk, 2018, HIV medicine.

Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study.

A. d’Arminio Monforte, P. Cicconi, S. Rusconi, 2003, The Journal of antimicrobial chemotherapy.

Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, K. Theys, 2013, The Journal of antimicrobial chemotherapy.

Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy

A. d’Arminio Monforte, S. Romagnoli, C. Tincati, 2016, AIDS.

Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort

A. d’Arminio Monforte, A. Antinori, C. Mussini, 2023, Liver international : official journal of the International Association for the Study of the Liver.

A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy

A. d’Arminio Monforte, B. Larder, J. Montaner, 2009, Artif. Intell. Medicine.

Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

A. Mocroft, A. d’Arminio Monforte, C. Sabin, 2018, Journal of the International AIDS Society.

Monkeypox epidemic in prisons: How to prevent it?

A. d’Arminio Monforte, D. Cereda, L. Tavoschi, 2022, The Lancet regional health. Europe.

Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy

A. d’Arminio Monforte, A. Antinori, G. Guaraldi, 2022, Journal of clinical medicine.

All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2012, International journal of epidemiology.

Incidence, Risk Factors and Impact on Clinical Outcomes of Bloodstream Infections in Patients Hospitalised with COVID-19: A Prospective Cohort Study

A. d’Arminio Monforte, F. Bai, M. Allegrini, 2021, Antibiotics.

Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

Ross J. Harris, J. Sterne, A. d’Arminio Monforte, 2008, AIDS.

Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America.

J. Sterne, O. Kirk, A. d’Arminio Monforte, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.

J. Sterne, O. Kirk, A. d’Arminio Monforte, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

An explainable model of host genetic interactions linked to COVID-19 severity

A. d’Arminio Monforte, M. L. La Rovere, M. Colaneri, 2022, Communications Biology.

Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study

A. d’Arminio Monforte, G. Ippolito, A. Antinori, 2001, Journal of NeuroVirology.

Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy.

A. d’Arminio Monforte, A. Antinori, P. Cinque, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Risk of tuberculosis following HIV seroconversion in high-income countries

C. Morrison, A. d’Arminio Monforte, C. Sabin, 2012, Thorax.

Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord

O. Kirk, A. d’Arminio Monforte, M. Egger, 2014, AIDS.